Genetic risk tools, including polygenic risk scores, do not perform equally well across all populations. This unequal performance stems from systematic underrepresentation in existing datasets and inherent biases within their modeling techniques. The consequence is a deepening of health care disparities for those already marginalized by the economic order.
Experts warn that if these performance gaps persist, the potential benefits of genetic risk scoring in disease prevention and management will remain limited. The current trajectory risks exacerbating health care inequalities, further entrenching a two-tiered system where effective care is a privilege, not a right. The tools, designed within a system that commodifies health, reflect its structural biases.
A System Built on Exclusion
Underrepresentation in genetic datasets is not an accident. It is a symptom of a healthcare system that historically underserves and extracts from specific communities while prioritizing the data and needs of dominant groups. This systematic exclusion means the very foundation of these predictive tools is flawed, built on an incomplete and biased understanding of human biology across diverse populations. The tools, therefore, function as designed by the prevailing economic logic: concentrating benefits where capital is already invested and neglecting those from whom it can extract little immediate profit.
The Market's 'Solution'
Researchers are now attempting to reduce this performance gap. Their proposed solutions include improved modeling techniques and broader recruitment of minority groups to diversify datasets. These efforts aim to make the existing tools function more 'fairly' within the established framework. However, they do not challenge the underlying economic structures that create health disparities in the first place. The focus remains on refining a product, not on dismantling the conditions that make such biased products inevitable.
This approach, while presented as a step towards equity, risks turning the collection of data from marginalized communities into another form of extraction. It seeks to 'fix' the tool without addressing the systemic underinvestment in community health, the lack of access to care, or the environmental injustices that disproportionately affect these same populations. The drive to diversify datasets, without a fundamental shift in healthcare's profit motive, can become another mechanism for capital to expand its reach, collecting valuable data from the dispossessed while offering only incremental, conditional improvements.
Deepening Disparities
The reporting highlights the unequal performance of these tools and the push to make them work more uniformly across different populations. Yet, it sidesteps the crucial question of why such disparities exist and persist. The problem isn't merely a technical glitch in an otherwise neutral system; it's a reflection of how wealth is concentrated and how access to health, like all other essential services, is dictated by class and race under capitalism. Without confronting the commodification of health and the systematic underpayment of labor that creates and maintains these health gaps, any 'solution' for genetic risk tools will remain a superficial patch on a deeply fractured system, ensuring that health apartheid continues to deepen.